Nebenwirkungen · MabThera
MabThera 1400 mg solution for subcutaneous injection · Abschnitt 4.8 · PDF-Seite 64
HOS-087679 · Präparat HOS-083527
Table 1 Adverse reactions reported in clinical trials or during post-marketing surveillance in patients with NHL and CLL disease treated with MabThera monotherapy/maintenance or incombination with chemotherapy MedDRA Very System Organ Common Uncommon Rare Very Rare Not known Common Class Infections and bacterial sepsis, serious viral progressive enteroviral infestations infections, +pneumonia, infection2, multifocal meningoencephal viral infections, +febrile infection, pneumocystis leukoencephalopat itis 2,3 +bronchitis +herpes zoster, jirovecii +respiratory tract pneumonia hy infection, fungal infections, infections of unknown aetiology, +acute bronchitis, +sinusitis,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T15:15:00Z · SHA-256 595c4e1a263e9a34be8b62842a5fc67f95f6a1b1f2a250341444a2960c6c3962 · Passage 65dbf3e4bdad5c8ab123deec8d5f22ed0793f5736df289fee23b8ffcea5480b2 · Zeichen 4100–5535 im Abschnitt